Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Position in Illumina, Inc. $ILMN

Fjarde AP Fonden Fourth Swedish National Pension Fund cut its position in Illumina, Inc. (NASDAQ:ILMN) by 16.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 29,186 shares of the life sciences company’s stock after selling 5,700 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $2,316,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Mariner LLC raised its holdings in shares of Illumina by 13.5% during the fourth quarter. Mariner LLC now owns 10,921 shares of the life sciences company’s stock valued at $1,459,000 after purchasing an additional 1,298 shares during the last quarter. CreativeOne Wealth LLC purchased a new position in shares of Illumina during the fourth quarter valued at approximately $248,000. Jump Financial LLC raised its holdings in shares of Illumina by 260.0% during the fourth quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company’s stock valued at $1,051,000 after purchasing an additional 5,680 shares during the last quarter. Farringdon Capital Ltd. purchased a new position in shares of Illumina during the fourth quarter valued at approximately $206,000. Finally, GeoWealth Management LLC raised its holdings in shares of Illumina by 17.7% during the fourth quarter. GeoWealth Management LLC now owns 2,706 shares of the life sciences company’s stock valued at $362,000 after purchasing an additional 406 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ILMN. Scotiabank cut shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Evercore ISI upped their price target on shares of Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Canaccord Genuity Group upped their target price on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Piper Sandler dropped their target price on shares of Illumina from $190.00 to $185.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. Finally, Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research report on Tuesday, August 12th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $124.58.

Illumina Trading Up 0.0%

Shares of ILMN opened at $100.11 on Monday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a market cap of $15.39 billion, a P/E ratio of 12.67, a P/E/G ratio of 2.25 and a beta of 1.37. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $96.81 and its 200-day simple moving average is $89.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm posted $0.36 earnings per share. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.